---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-182544"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2024-07-23T23:59:59+00:00"
generated_at: "2026-05-31T18:07:11.565165+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics to present interim 4D-150 wet AMD data at September 2024 medical conference

## Summary
- Interim data from Phase 1/2 PRISM trial (Dose Expansion, Phase 2 Dose Expansion, Phase 2 Population Expansion cohorts) expected at September 2024 medical conference.
- Specific forum and date to be disclosed with Q2 2024 financial results in August 2024.
- 52-week landmark analyses for Dose Expansion and Population Expansion cohorts on track for February 2025 as previously disclosed.

## SEC filing metadata
- accession: 0001193125-24-182544
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2024-07-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312524182544/0001193125-24-182544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312524182544/d864314d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-182544
- JSON: https://secwatch.observer/filing/0001193125-24-182544.json
- Plain text: https://secwatch.observer/filing/0001193125-24-182544.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.